The weekly litigation news digest is live. Subscribe now

IP Verse

New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi) - EP4321157

The patent EP4321157 was granted to Novartis on Oct 23, 2024. The application was filed on Aug 26, 2014 under application number EP23202190A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4321157

NOVARTIS
Application Number
EP23202190A
Filing Date
Aug 26, 2014
Status
Granted And Under Opposition
Sep 20, 2024
Publication Date
Oct 23, 2024
External Links
Slate, Register, Google Patents

Patent Summary

A medicament for preventing or delaying cardiovascular mortality and hospitalizations in patients with chronic systolic heart failure, comprising a therapeutically effective amount of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) pro-drug in a 1:1 molar ratio. The medicament significantly reduces the risk of cardiovascular death and hospitalization for heart failure compared to standard ACE inhibitor therapy in patients with reduced ejection fraction.

Patent Family

Patent Family

Patent Oppositions (18)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ALFRED E TIEFENBACHERJul 23, 2025HAMM & WITTKOPPADMISSIBLE
BETAPHARM ARZNEIMITTELJul 23, 2025HAMM & WITTKOPPADMISSIBLE
HAMM & WITTKOPPJul 23, 2025HAMM & WITTKOPPADMISSIBLE
KRKAJul 23, 2025HOFFMANN EITLEADMISSIBLE
LANYON OPPOSITIONSJul 23, 2025PINSENT MASONSADMISSIBLE
POLPHARMAJul 23, 2025HAMM & WITTKOPPADMISSIBLE
WUESTHOFF & WUESTHOFFJul 23, 2025SONNENHAUSERADMISSIBLE
HAMM & WITTKOPPJul 23, 2025HAMM & WITTKOPPWITHDRAWN
BULLE DRJul 22, 2025KUTZENBERGER WOLFF & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSJul 22, 2025D YOUNGADMISSIBLE
DEVA HOLDINGJul 22, 2025-WITHDRAWN
CAMULONJul 21, 2025REDDIE & GROSEADMISSIBLE
ELPEN PHARMACEUTICALJul 21, 2025HASELTINE LAKE KEMPNERADMISSIBLE
EGISJul 18, 2025STOLMAR & PARTNERADMISSIBLE
DR SCHONJul 16, 2025DR SCHONADMISSIBLE
SYNTHONJul 14, 2025HOFFMANN EITLEADMISSIBLE
GENERICS UKJul 1, 2025ELKINGTON AND FIFEADMISSIBLE
ZENTIVA KSJun 25, 2025GREINERADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
OPPOSITIONUS2013158088
OPPOSITIONWO03059345
OPPOSITIONWO2007056546
OPPOSITIONWO2012027237
OPPOSITIONWO2014029848
OPPOSITIONWO2015028941
OTHEREP3626270
SEARCHUS2013158088
SEARCHWO2007056546

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents